Focal therapy for medium-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has a Gleason score of 7 (a moderate grade – 3+4 or 4+3).
- Your PSA level is 20 ng/mL or lower.
- The cancer is still inside the prostate (stage T2b or less).
- You are expected to live 10 more years or more.
- You have not had any previous treatment for prostate cancer and have no other active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks men with intermediate-risk prostate cancer who had a newer, targeted treatment that only treats the cancer area, not the whole prostate. It aims to see how well these treatments work in real life and may help guide future care.
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
This registry tracks men with early-stage prostate cancer who choose focal therapy—a targeted treatment that destroys only the cancer area while preserving healthy prostate tissue. The study helps doctors understand how well this approach works and its safety.
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.